Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

Share Price is delayed by 15 minutes
Get Live Data
0.49    -0.01 (-2.00%)
Bid:
0.47
Ask:
0.55
Spread: 0.08 (17.021%)
Market Cap: £2.85m
FUM Live PriceLast checked at - London Stock Exchange

Intraday Futura Medical Share Chart

Directorate Changes

20 Feb 2018 07:00

RNS Number : 3598F
Futura Medical PLC
20 February 2018
 

For immediate release

20 February 2018

 

 

 

 

 

Futura Medical plc

("Futura" or "the Company")

 

Directorate Changes

 

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, announces that Derek Martin, the Company's Finance Director, has resigned from the Board and will leave the Company with effect from the date of this announcement to pursue other business interests.

 

Angela Hildreth will join the Company in the role of Finance Director, Chief Operating Officer and Board Director with effect from the date of this announcement. Angela is an experienced executive with a track record gained in financial, operational and strategic roles in healthcare and other industries. Angela's experience includes the AIM market and development-stage companies.

 

Angela was most recently the UK finance director of Shield Therapeutics plc, having joined the business as its financial controller in 2011 when it was an unquoted start-up. Her breadth of roles at the business included finance, business development, human resources and IT.

 

James Barder, Futura's Chief Executive, said: "On behalf of the Board, I would like to thank Derek for his contribution to the development of the Company during almost 10 years as Finance Director having been appointed on 24 September 2008. We wish him all the best in his future activities.

 

"I am delighted to welcome Angela to the role of FD and COO at Futura. Her breadth of knowledge and commercial experience in the pharmaceutical sector will be of great value to the Company at a key stage in our development."

 

 

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Angela Hildreth (née Bowman), aged 38 years, has been a director of the following companies during the five years preceding the date of this announcement:

 

Current directorships Past directorships

Quaff Box Limited Shield Therapeutics Switzerland AG

Shield TX UK Limited

Phosphate Therapeutics Limited

 

There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

 

 

For any further information please contact:

 

 

Futura Medical plc

 

James Barder, Chief Executive

 

Tel: +44 (0)1483 685 670

mail to: james.barder@futuramedical.com

www.futuramedical.com

 

 

 

N+1 Singer (Nominated Adviser and Broker)

 

Aubrey Powell / Liz Yong

 

Tel:+44 (0) 20 7496 3000

 

 

For media enquiries please contact:

 

 

Buchanan

 

Mark Court / Sophie Wills / Stephanie Watson

Tel: +44 (0)20 7466 5000

 

 

 

Notes to Editors

 

Futura Medical plc

 

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

 

www.futuramedical.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAMMGZZVGFGRZG
Date   Source Headline
31st Oct 20089:58 amRNSMajor Interest in Shares
9th Oct 20081:59 pmRNSMAJOR INTEREST IN SHARES
26th Sep 200811:10 amRNSCorporate Brokership
24th Sep 20087:00 amRNSBoard Appointment
19th Sep 20087:00 amRNSInterim Results
5th Sep 20087:00 amRNSNotice of Interim Results
7th May 20087:00 amRNSAGM Statement
9th Apr 20087:00 amRNSProject Update
3rd Apr 20087:00 amRNSAnnual Report and AGM Notice
31st Mar 20087:01 amRNSBoard Change
25th Mar 20087:01 amRNSAnnual Report and Accounts
13th Mar 20087:00 amRNSPreliminary Results
4th Mar 20087:01 amRNSNotification of Results
16th Jan 200812:31 pmRNSMajor Interest in Shares
10th Jan 20088:00 amRNSDirector's Share Transfer
3rd Jan 20088:00 amRNSDirector's Share Transfer
7th Dec 20077:00 amRNSLong Term Incentive Scheme
15th Nov 20077:01 amRNSIssue of Equity
24th Sep 20077:02 amRNSInterim Results
18th Sep 20077:00 amRNSNotice of Results
17th Sep 20079:08 amRNSMED2002 Licensing Deal
23rd Aug 20077:00 amRNSAppt of Pain Relief Adviser
14th Aug 20071:31 pmRNSHolding(s) in Company
9th Aug 20077:01 amRNSPositive Study Results
2nd Aug 20073:59 pmRNSHoldings in Company
27th Jul 20077:00 amRNSGrant Approval
19th Jul 20077:00 amRNSResult of AGM
20th Jun 20077:02 amRNSAnnual Report & Accounts
30th May 20077:02 amRNSFinal Results
25th May 200710:33 amRNSNotice of Preliminary Results
17th May 20077:01 amRNSHolding(s) in Company
14th May 20077:02 amRNSMED2002 Update
9th May 20077:02 amRNSCSD500 Patents granted
4th May 20077:01 amRNSConference Presentation
18th Apr 20077:01 amRNSDermaSys Agreement with GSK
22nd Mar 200711:02 amRNSHolding(s) in Company
20th Mar 20077:01 amRNSHolding(s) in Company
28th Feb 20077:01 amRNSLaunch of DermaSys Brand
31st Jan 20078:00 amRNSAdditional Listing
18th Jan 200712:52 pmRNSHolding(s) in Company
20th Dec 20067:01 amRNSTotal Voting Rights
16th Nov 20067:01 amRNSCSD500 Regulatory Update
12th Oct 20067:00 amRNSTechnical Seminar
21st Sep 20067:01 amRNSInterim Results
7th Sep 20067:00 amRNSNotice of Interim Results
6th Sep 20067:01 amRNSDCF100 Skin Study Results
17th Jul 20067:00 amRNSFLD500 Scale-up Trials
6th Jul 20067:01 amRNSNew Product Update
4th Jul 20062:44 pmRNSIssue of Equity
4th Jul 20062:39 pmRNSAgreement with GSK

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.